AzTrials
AzTrials

Liver FailureLTNCT04122027

A Prospective Randomized Controlled Trial on the Use of Cerebral Oximetry in Adult Chinese Patients Undergoing Liver Transplantation

A study testing Cerebral oximeter in people with Liver Failure, run by The University of Hong Kong at 2 sites in 2 countries.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Liver transplantation (LT) is a life-saving procedure for patients with end-stage liver diseases. Although with continuous advancement in technology, it remains a high-risk operation. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Liver Failure
What is being tested?
Cerebral oximeter
Could I receive a placebo?
No, everyone receives an active treatment
How many people
158 participants
Where
2 sitesin 2 countries
Study dates
30 Jul 2018to 31 May 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Able to get informed consent by patient
  • Patients undergo DDLT or LDLT at Department of Surgery, Liver Transplant Centre, The University of Hong Kong, Queen Mary Hospital
  • Ethnicity is Chinese

Who cannot join

  • Refusal of consent by patient
  • Pre-existing neurological damage, history of seizures and on antidepressants
  • Skin conditions over forehead that precludes the application of sensors of equipment
  • Ethnicity is not Chinese

Trial locations and contacts

2 sites in 2 countries.

Kenneth Chok, MBBS, MS, FRCS, FCSHK, FHKAM contact

22553025 ext. 085222554848

chok6275@hku.hk

2 sites in 2 countries

China1 site, 1 recruiting
  • Queen Mary Hospital

    Hong Kong

    Kenneth Siu-Ho Chok, 852 22553025 ext. 085222554848, chok6275@hku.hk

    Recruiting

Other trials in China

Hong Kong1 site, 1 recruiting
  • Queen mary Hospital

    Hong Kong

    Recruiting

Other trials in Hong Kong

About this study

Official title: Use of Cerebral Oximetry In Adult Chinese Patients For Liver Transplantation

Liver transplantation (LT) is a life-saving procedure for patients with end-stage liver diseases. Although with continuous advancement in technology, it remains a high-risk operation. The goal of LT is not only ensure survival of the patients but also to restore them back to their pre-morbid state with a good quality of life. Neurological sequelae can have major impact on postoperative outcomes after LT and yet the reported literature is scarce. Studies from Western countries showed some evidence on the use of cerebral oximtery in cardiac surgery to prevent neurological mishaps. LT shares similar intra-operative fluctuation of the haemodynamices as in cardiac surgery, causing disturbances in regional cerebral oxygenation and theorectically cerebral oximetry should be of great value as well in LT surgery. Data from a large randomised controlled trial is lacking from the current literatures. We therefore propose a prospective randomized controlled trial on the use of this device in adult LT and see whether its use could reduce neurological mishaps.

Read the detailed description

Liver Transplant Liver transplantation (LT) is a life-saving procedure for patients with end-stage liver disease. Despite continuous advancement in technology, it remains a high-risk operation. The building-up of an oxygen debt during LT can lead to an increased risk of poor postoperative outcomes (1, 2). Furthermore, patients with acute liver failure or end-stage liver disease are prone to hepatic encephalopathy, which can lead to disturbance of auto-regulation in the brain, which may eventually cause cerebral hypoxia and ischaemia. Irresversible metabolic disturbances can impair cerebral auto-regulation, causing poor neurological outcomes after LT (3). The prevalence of encephalopathy, delirium and stroke in transplant recipients is 12-40% (3). Hypotheses for these conditions include prolonged stay in the intensive care unit (ICU) (so-called "ICU psychosis"), the use of Tacrolimus (4), rapid correction of hyponatraemia (5) and impaired cerebral auto-regulation (3), but no definite conclusion can be made most of the time. Among these hypotheses, impairment of cerebral auto-regulation has never been documented in large clinical trials for Chinese patients in LT.

Cerebral oximetry (Near infra-red spectroscopy, NIRS) There is no "gold standard" for measuring cerebral auto-regulation. Monitoring of the brain oxygenation, such as direct tissue O2 tension and jugular bulb O2 saturation, has been used as a surrogate of auto-regulation but it is invasive. Transcranial laser Doppler (TCD) of the middle cerebral artery has been validated in healthy volunteers as well as real patients as a good measurement of cerebral blood flow (6, 7). Similarly, near-infrared spectroscopy (NIRS), a non-invasive and continuous method, can also monitor the regional cerebral oxygenation (rScO2) and is increasingly used in cardiac surgery. A previous report has validated the use of NIRS when compared to TCD, as the latter requires a trained technician to monitor and supervise. NIRS provides a timely, real-time, inexpensive, easily measurable alternative to TCD, and thus should have a great potential for clinical usage in LT. Similar to other non-invasive oximetry (e.g. pulse oximetry), measurement can be done through adhesive tapes over bilateral forehead and connected to the machine (INVOS™ 5100C Cerebral/Somatic Oximeter by Covidien). This system is the ONLY cerebral/somatic oximetry system with FDA cleared improved outcome claims (8). Plachky et al. showed that 50% of patients demonstrated a decline in cerebral oxygen saturation when clamping of the vessles during LT and it had positive correlation with the postoperative cerebral disrubances (9). Nonetheless, the clinical application for patients undergoing LT is scarce and its application is novel. The use of this technology may potenitally be limited by the presence of high levels of bilirubin acting as a chromophore interferring with its data acquistion. However, in a pilot study of 9 patients who underwent LT investigators using this technology were able to demonstrate that 3 out of 9 patients had either transient or persistent impaired auto regulation throughout the operation. This in turn was associated with higher Model of End-Stage Disease Score (MELD) >15 (p=0.015), more postoperative seizures and stroke (P<0.0001) (3). A recent systematic review (10) of 901 Caucasians from 24 publications showing a decrease in NIRS (>15% relative to baseline) could have impaired postoperative cognitive function (28 versus 26; MMSE) and reduced LOS (14 versus 23 days) in open surgery. In the field of LT, impaired cerebral autoregulation (25%), cerebral deoxygenation in the anhepatic phase (36%) and cerebral hyperoxygenation with reperfusion of the grafted liver (14%) were identified by NIRS and could lead to adverse neurological outcome such as seizures, transient hemiparesis and stroke. Nonetheless, no large prospective randomized trial and no Chinese cohort were included.

References

  1. Shoemaker WC, Appel PL, Kram HB. Role of oxygen debt in the development of organ failure sepsis, and death in high-risk surgical patients. Chest. 1992;102(1):208-15.
  2. Shoemaker WC, Appel PL, Kram HB. Hemodynamic and oxygen transport responses in survivors and nonsurvivors of high-risk surgery. Critical care medicine. 1993;21(7):977-90.
  3. Lescot T, Karvellas CJ, Chaudhury P, Tchervenkov J, Paraskevas S, Barkun J, et al. Postoperative delirium in the intensive care unit predicts worse outcomes in liver transplant recipients. Can J Gastroenterol. 2013;27(4):207-12.
  4. DiMartini AF, Trzepacz PT, Pajer KA, Faett D, Fung J. Neuropsychiatric side effects of FK506 vs. cyclosporine A. First-week postoperative findings. Psychosomatics. 1997;38(6):565-9.
  5. Lee J, Kim DK, Lee JW, Oh KH, Oh YK, Na KY, et al. Rapid Correction Rate of Hyponatremia as an Independent Risk Factor for Neurological Complication Following Liver Transplantation. Tohoku J Exp Med. 2013;229(2):97-105.
  6. Lang EW, Mehdorn HM, Dorsch NW, Czosnyka M. Continuous monitoring of cerebrovascular autoregulation: a validation study. Journal of neurology, neurosurgery, and psychiatry. 2002;72(5):583-6.
  7. Ono M, Zheng Y, Joshi B, Sigl JC, Hogue CW. Validation of a stand-alone near-infrared spectroscopy system for monitoring cerebral autoregulation during cardiac surgery. Anesthesia and analgesia. 2013;116(1):198-204.
  8. Murkin JM, Adams SJ, Novick RJ, Quantz M, Bainbridge D, Iglesias I, et al. Monitoring brain oxygen saturation during coronary bypass surgery: a randomized, prospective study. Anesthesia and analgesia. 2007;104(1):51-8.
  9. Plachky J, Hofer S, Volkmann M, Martin E, Bardenheuer HJ, Weigand MA. Regional cerebral oxygen saturation is a sensitive marker of cerebral hypoperfusion during orthotopic liver transplantation. Anesth Analg. 2004;99(2):344-9.
  10. Sorensen H, Grocott HP, Secher NH. Near infrared spectroscopy for frontal lobe oxygenation during non-vascular abdominal surgery. Clin Physiol Funct Imaging. 2016;36(6):427-35.
Conditions
Liver Failure
Being tested
Cerebral oximeter
Medical subject headings
Liver Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cerebral oximeterOther

    Near infra-red spectroscopy, NIRS

Study groups in NCT04122027
Study groupRoleWhat they receive
ControlActive comparatorPatients undergoing liver transplantation without regional cerebral oxygenation monitoring using a cerebral oximeter.
Receives: Other: Cerebral oximeter
InterventionActive comparatorPatients undergoing liver transplantation with regional cerebral oxygenation monitoring using a cerebral oximeter.
Receives: Other: Cerebral oximeter

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Duration of confusion as assessed by the Confusion Assessment method

    To assess patients experience of development of delirium

    Measured: 48 hours after liver transplant

Secondary outcomes (2)
  1. The time taken for MOCA to return to baseline

    To assess the time patients required to return health conditions within 10 days after surgery

    Measured: 10 days after liver transplant

  2. Other complications unrelated to neurological deficit according to Clavien-Dino Classification.

    To monitor any other complications developed by patients after liver transplant

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Oct 2019
  2. Study start30 Jul 2018
  3. Primary completion31 May 2020 (estimated)
  4. Study completion31 May 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
158 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04122027
Sponsor's protocol ID
UW 18-321
Acronym
LT
Status last verified
Oct 2019
First submitted
9 Oct 2019
Last updated
10 Oct 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Cerebral oximeter in people with Liver Failure, run by The University of Hong Kong at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in China, Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Kenneth Chok, MBBS, MS, FRCS, FCSHK, FHKAM (22553025 ext. 085222554848, chok6275@hku.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Duration of confusion as assessed by the Confusion Assessment method (time frame: 48 hours after liver transplant). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in